Expertise in
4
conditions

Cecile Borel

Toulouse, FR 
Expertise in
4
conditions
Toulouse, FR 

Overview

Cecile Borel practices practicing medicine in Toulouse, France.

Ms. Borel is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Adult Immune Thrombocytopenia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Toulouse, France
Other Locations
CHU de Nantes
Nantes, France
Strasbourg, France
Nancy, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug, Radiation
Study Drugs: Brentuximab, Cyclophosphamide, Adriamycin, Oncovin, Bleomycin, Etoposide, Procarbazine, Prednisone, Filgrastim
Study Phase: Phase 2
View 1 Less Clinical Trial

54 Total Publications

Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.
Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.
Journal: Haematologica
Published: May 04, 2026

Frequently Asked Questions about Cecile Borel

Is Cecile Borel a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Cecile Borel is classified as an Distinguished expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cecile Borel participate in research or clinical trials?

Yes. Cecile Borel has published 54 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Cecile Borel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Borel's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile